Jump Financial LLC Takes Position in Repligen Corporation $RGEN

Jump Financial LLC bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,694 shares of the biotechnology company's stock, valued at approximately $343,000.

Several other hedge funds have also recently made changes to their positions in the business. Stifel Financial Corp lifted its position in Repligen by 12.1% during the 4th quarter. Stifel Financial Corp now owns 4,939 shares of the biotechnology company's stock valued at $711,000 after acquiring an additional 535 shares during the period. Northern Trust Corp grew its stake in shares of Repligen by 26.0% during the 4th quarter. Northern Trust Corp now owns 493,713 shares of the biotechnology company's stock valued at $71,065,000 after purchasing an additional 102,011 shares during the period. Algert Global LLC purchased a new stake in shares of Repligen in the 4th quarter worth $844,000. Bayesian Capital Management LP purchased a new position in shares of Repligen during the 4th quarter valued at about $947,000. Finally, Bridgefront Capital LLC purchased a new stake in shares of Repligen in the fourth quarter worth $562,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Repligen

In other news, Director Martin D. Madaus purchased 1,800 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the purchase, the director directly owned 1,800 shares of the company's stock, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 1.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 price objective for the company in a report on Tuesday, July 22nd. Wells Fargo & Company dropped their price objective on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a report on Wednesday, July 30th. Evercore ISI lowered their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. HC Wainwright restated a "buy" rating and set a $180.00 price target on shares of Repligen in a research note on Wednesday. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $205.00 price target on shares of Repligen in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Repligen currently has an average rating of "Moderate Buy" and an average target price of $169.55.

Repligen Stock Up 3.8%

Repligen stock traded up $4.40 during mid-day trading on Thursday, hitting $120.58. The company had a trading volume of 841,555 shares, compared to its average volume of 653,366. The business has a fifty day moving average of $121.51 and a 200 day moving average of $129.58. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The stock has a market cap of $6.78 billion, a price-to-earnings ratio of -482.30, a PEG ratio of 2.14 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. During the same quarter last year, the business posted $0.40 earnings per share. The company's revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, sell-side analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.